A review of immune-related adverse events associated with immunotherapy
10.3760/cma.j.issn.0253-3766.2020.01.002
- VernacularTitle: 肿瘤免疫治疗中不可忽视的免疫相关不良反应
- Author:
Yuan FANG
1
;
Yue YU
;
Dawei WU
;
Hong FANG
;
Huiyao HUANG
;
Shuhang WANG
;
Anqi YU
;
Chao SUN
;
Ying BAI
;
Hui WANG
;
Ning LI
Author Information
1. GCP center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Review
- Keywords:
Immune checkpoint inhibitor;
Immune related adverse events;
PD-1 inhibitor;
PD-L1 inhibitor
- From:
Chinese Journal of Oncology
2020;42(1):17-21
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors have been approved for clinical application in China. However, the increased immune-related adverse event (irAE) needs more attention. This review summarized the incidence, characteristic clinical manifestation and treatment of irAEs associated with programmed cell death protein-1(PD-1) and programmed cell death ligand-1(PD-L1) inhibitors. To have a deep insight into irAE, the potential mechanisms, the different incidences of cancer types, influencing factors and the direction of future research were also discussed here to provide guidance for clinical oncologist to identify and monitor irAE.
